Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Martí Carvajal, Arturo ^a   Perez Requejo J L ^b  

^a Centro Colaborador Venezolano de la Red Cochrane Iberoamericana   (Venezuela)

^b NONE

Author keywords

Amino acids *therapeutic use ; Antifibrinolytic agents *therapeutic use ; Blood coagulation disorders etiology; *therapy ; Humans; Liver diseases *complications

Indexed keywords

AMINO ACID DERIVATIVE; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTIPLASMIN; D DIMER; FIBRIN; PLASMIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

ABDOMINAL PAIN; BLOOD CLOTTING DISORDER; COCHRANE LIBRARY; DATA ANALYSIS; DIARRHEA; DRUG EFFICACY; EMBASE; HEMOSTASIS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MEDLINE; MORTALITY; NAUSEA; OUTCOMES RESEARCH; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS; UPPER GASTROINTESTINAL BLEEDING; VOMITING;

EID: 44949194909     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006007.pub2     Document Type: Review

References (41)

1. Barer 1983 Barer D, Ogilvie A, Henry D, Dronfield M, Coggon D, French S, et al.Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding. New England Journal of Medicine 1983;308:1571-5.
2. Bergqvist 1980 Bergqvist D, Dahlgren S, Hessman Y. Local inhibition of the fibrinolytic system in patients with massive upper gastrointestinal hemorrhage. Upsala Journal of Medical Sciences 1980;85:173-8.
3. Biggs 1976 Biggs JC, Hugh TB, Dodds AJ. Tranexamic acid and upper gastrointestinal haemorrhage: a double-blind trial. Gut 1976;17:729-34.
4. Cormak 1973 Cormack F, Chakrabarti RR, Jouhar AJ, Fearnley GR. Tranexamic acid in upper gastrointestinal haemorrhage. The Lancet 1973;1(7814):1207-8.
5. Engqvist 1979 Engqvist A, Brostrom O, von Feilitzen F, Halldin M, Nystrom B, Ost A, et al.Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study. Scandinavian Journal of Gastroenterology 1979;14:839-44.
6. von Holstein 1987 von Holstein CC, Eriksson SB, Kallen R. Tranexamic acid as an aid to reducing blood transfusion requirements in gastric and duodenal bleeding. British Medical Journal (Clinical research ed.) 1987;294:7-10.
7. Agarwal 2000 Agarwal S, Joyner KA Jr, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. American Journal of Gastroenterology 2000;95(11):3218-24.
8. Alderson 2004 Alderson P. Absence of evidence is not evidence of absence. BMJ (Clinical Research Ed.) 2004;328:476-7.
9. Amitrano 2002 Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Seminars in Liver Disease 2002;22:83-96.
10. Cesarman-Maus 2005 Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. British Journal of Haematology 2005;129:307-21.
11. Chalmers 2004 Chalmers I. Well informed uncertainties about the effects of treatments. How clinicians and patients respond?. BMJ (Clinical Research Ed.) 2004;328:475-6.
12. Chiu 2002 Chiu J, Ketchum LH, Reid TJ. Transfusion-sparing hemostatic agents. Current Opinion in Hematolology 2002;9(6):544- 50.
13. Cohen 1993 Cohen H, Hunt JB, Dixit M, Kanwar S, Thomas HC. Decreased contact factor mediated fibrinolysis in cirrhosis. British Journal of Haematolology 1993;85(3):542-5.
14. Colucci 2003 Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003;38(1):230-7.
15. DeLoughery 1999 DeLoughery TG. Management of bleeding with uremia and liver disease. Current Opinion in Hematolology 1999;6(5):329- 33.
16. Dunn 1999 Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57(6):1005-32.
17. Egger 1997 Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
18. Gluud 2006 Gluud C, Als-Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, et al. Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art.No.: LIVER.
19. Hedner 2002 Hedner U. General haemostatic agents-fact or fiction?. Pathophysiology of Haemostasis and Thrombosis 2002;32(Suppl 1):33-6.
20. Henry 1989 Henry DA, O'Connell DL. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ (Clinical Research Ed.) 1989;298(6681):1142-8.
21. Henry 1993 Henry DA. Fibrinolysis and upper gastrointestinal bleeding. The Lancet 1993;341:527-8.
22. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ (Clinical Research Ed.) 2003;327 (7414):557-60.
23. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. http: //www.cochrane.org/resources/handbook/hbook.htm (accessed 20 September 2006).
24. Hu 2001 Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. American Journal of Gastroenterology 2001;96(5):1581- 6.
25. ICH-GCP 1997 International Committee on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulations & Guidelines. Philadelphia, US: Barnett International/PAREXEL, 1997.
26. Ioannidis 2004 Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141:781-8.
27. Mannucci 1998 Mannucci PM. Hemostatic drugs. New England Journal of Medicine 1998;339:245-53.
28. Moher 2004 Moher D, Altman DG, Schulz KF, Elbourne DR. Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond. Canadian Medical Association Journal 2004;171:349-50.
29. Pernambuco 1993 Pernambuco JR, Langley PG, Hughes RD, Izumi S, Williams R. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 1993;18(6):1350-6.
30. Piscaglia 2000 Piscaglia F, Siringo S, Hermida RC, Legnani C, Valgimigli M, Donati G, et al. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology 2000;31(2):349- 57.
31. Piscaglia 2001 Piscaglia F, Donati G, Giannini R, Bolondi L. Liver cirrhosis, ascites, and hyperfibrinolysis. American Journal of Gastroenterology 2001;96(11):3222.
32. RevMan 2003 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
33. Royle 2003 Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
34. Serov 1991 Serov NA, Sukhanov VA, Podymova SD. Fibrinolysis as a cause of coagulopathy in patients with chronic diffuse diseases of the liver. Klinicheskaia Meditsina 1991;69(4):73-5.
35. Song 1993 Song KS, Kim HS, Park KE, Kwon OH. The fibrinogen degradation products (FgDP) levels in liver disease. Yonsei Medical Journal 1993; 34(3):234-8.
36. Takahashi 1990 Takahashi H, Tatewaki W, Wada K, Niwano H, Shibata A. Fibrinolysis and fibrinogenolysis in liver disease. American Journal of Hematology 1990;34(4):241-5.
37. Toschi 1993 Toschi V, Rocchini GM, Motta A, Fiorini GF, Cimminiello C, Violi F, et al. The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites. Biomedicine & Pharmacotherapy 1993;47(8):345-52.
38. Van Thiel 2004 Van Thiel DH, George M, Mindikoglu AL, Baluch MH, Dhillon S. Coagulation and fibrinolysis in individuals with advanced liver disease [Geç dönem karacioer hastalýklarýnda koagulasyon ve fibrinolizis]. The Turkish Journal of Gastroenterology 2004;15:67-72.
39. Verstraete 1985 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29(3):236-61.
40. Violi 1992 Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al.Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992;15(4):672-6.
41. Violi 1993 Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, et al.Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation abnormalities in liver cirrhosis. Hepatology 1993;17(1):78-83.